
CCCC Stock Price
C4 Therapeutics, Inc.
CCCC stock price is $2.48 (+1.64% on the day), giving C4 Therapeutics, Inc. a market cap of $325.67M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
CCCC Stock Overview
- Price
- $2.48
- Previous close
- $2.44
- Open
- $2.39
- Market cap
- $325.67M
- 52-week range
- $1.69 - $5.17
- 1-year price target
- $12.50
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- Nasdaq
- MarketXLS Rank
- 43
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant to treat melanoma, colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC under preclinical stage. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA, Darmstadt, Germany; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CCCC | $2.48 | +1.6% | 3.63M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |